Weve also seen data that semaglutide has been shown to have anti-inflammatory and cardiovascular benefits, which can further protect the kidneys from damage. If the heart pumps better, Whyte added, the kidney is going to function better. The role of GLP-1 medications for treating obesity is just one of several surprising findings uncovered since their introduction to the market
Shiva Houjeghan1, Sorayya Kheirouri, Esmaeil Faraji,Mohammad Asghari Jafarabadi
tirzepatide lowered HbA 1c by 2.01 to 2.30 percentage points versus 1.86 for semaglutide, meeting non-inferiority and superiority, with greater weight loss as well
Reduction of Glucagon : These medications decrease the secretion of glucagon, a hormone that raises blood sugar levels, further aiding in maintaining optimal glucose levels
KLOW and GLP-1 medications act through different receptor systems while there is no direct synergy, KLOW can support tissue healing from training and reduce inflammation during GLP-1-induced rapid weight loss
Johnson, AMF and Olefsky JM (2013)